Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
26.49
-0.99 (-3.60%)
At close: Jun 5, 2026, 4:00 PM EDT
26.42
-0.07 (-0.28%)
After-hours: Jun 5, 2026, 4:15 PM EDT
Neurogene Market Cap
Neurogene has a market cap or net worth of $418.59 million as of June 5, 2026. Its market cap has increased by 67.81% in one year.
Market Cap
418.59M
Enterprise Value
184.54M
1-Year Change
67.81%
Ranking
Category
Stock Price
$26.49
Market Cap Chart
Since December 19, 2023, Neurogene's market cap has increased from $193.64M to $418.59M, an increase of 116.17%. That is a compound annual growth rate of 36.75%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 5, 2026 | 418.59M | 31.18% |
| Dec 31, 2025 | 319.09M | -6.03% |
| Dec 31, 2024 | 339.58M | 36.64% |
| Dec 29, 2023 | 248.52M | 28.34% |
| Dec 19, 2023 | 193.64M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ocugen | 433.31M |
| Sutro Biopharma | 432.32M |
| Contineum Therapeutics | 429.38M |
| Eupraxia Pharmaceuticals | 424.34M |
| C4 Therapeutics | 424.20M |
| Sagimet Biosciences | 417.44M |
| Editas Medicine | 415.88M |
| Indaptus Therapeutics | 414.47M |